Saturday 17 October 2026
Export ELVN’s income statement to Excel — free account
Enliven Therapeutics, Inc.
ELVN Healthcare Biotechnology
In the quarter to June 2026, EPS was flat and free cash flow fell 8.34%, each against the same quarter a year earlier.
37.32
2.01
−5.11%
Follow ELVN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 53.60 | 8.56 | 3.90 | 9.80 | 10.90 | 13.30 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 250.84 | 96.40 | 21.04 | 25.34 | 30.03 | 25.37 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 20 | 27 | 41 | 6 | 46 | 62 | 60 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | 0 | (11) | (23) | (41) | (51) | (38) | (72) | (89) | (104) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (11) | (23) | (41) | (51) | (38) | (72) | (89) | (104) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | (4) | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (2.62) | (133.61) | (14.12) | (9.48) | (12.05) | (2.01) | (1.89) | (1.83) | |||||
| Cash flow | — | (0.51) | (2.03) | (124.58) | (10.74) | (8.64) | (10.27) | (1.72) | (1.55) | (1.24) | |||||
| Capex | — | 0.00 | 0.00 | (0.80) | (0.01) | 0.00 | (0.20) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | (0.51) | (2.03) | (125.38) | (10.75) | (8.64) | (10.46) | (1.73) | (1.56) | (1.24) | |||||
| Book value | — | (0.90) | (6.09) | 164.67 | 24.25 | 15.89 | 23.34 | 6.92 | 6.58 | 8.11 | |||||
| Shares, m | — | 17 | 4 | 0 | 3 | 5 | 3 | 36 | 47 | 57 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | (9) | (9) | (22) | (37) | (47) | (32) | (61) | (73) | (70) | ||||
| Capex | — | — | — | 0 | 0 | 0 | (1) | 0 | 0 | 0 | |||||
| Free cash flow | — | (9) | (9) | (22) | (37) | (47) | (33) | (61) | (73) | (70) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 9 | 6 | 26 | 84 | 85 | 68 | 240 | 302 | 458 | ||||
| Total debt | — | 1 | — | — | — | 1 | — | — | — | — | |||||
| Net debt | — | (9) | (7) | (29) | (88) | (90) | (76) | (253) | (313) | (463) | |||||
| Shareholders’ equity | — | (16) | (26) | 29 | 84 | 86 | 73 | 246 | 310 | 460 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | 0.00 | (294.28) | (114.45) | (79.29) | (55.70) | (42.57) | (40.31) | (29.79) | (25.86) | ||||
| ROIC | — | 0.00 | 0.00 | (167,472.22) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 0.00 | 54.18 | 62.43 | (276.61) | (60.29) | (818.29) | (84.67) | (32.04) | (26.95) | |||||
Negative figures in brackets.
Charts ten years each
Enliven Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CELC Celcuity, Inc. | $3.0B | — (loss-making) | — | — | n/m | −53.27% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DNLI Denali Therapeutics Inc. | $2.9B | — (loss-making) | — (loss-making) | −89.74% (below 0%: shrinking) | n/m | −22.91% (below 0%: shrinking) | 97.42% | (3,622.11%) | Compare |
| RCUS Arcus Biosciences, Inc. | $2.9B | — (loss-making) | — (loss-making) | −74.38% (below 0%: shrinking) | n/m | +10.53% (above 0%: growing) | 100.00% | (234.15%) | Compare |
| ELVN Enliven Therapeutics, Inc. | $2.9B | — (loss-making) | — | — | n/m | −8.34% (below 0%: shrinking) | 0.00% | 0.00% | |
| DYN Dyne Therapeutics, Inc. | $2.9B | — (loss-making) | — | — | n/m | −39.08% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NRIX Nurix Therapeutics, Inc. | $2.7B | 9.7× | — (loss-making) | +8,426.27% (above 0%: growing) | n/m | +1,122.10% (above 0%: growing) | 100.00% | 83.12% | Compare |
| ZLAB Zai Lab Limited Unsponsored ADR | $2.7B | — (loss-making) | — (loss-making) | −3.33% (below 0%: shrinking) | n/m | −84.42% (below 0%: shrinking) | 54.70% | (71.95%) | Compare |
| PGEN Precigen, Inc. | $2.6B | — (loss-making) | — (loss-making) | +6,322.66% (above 0%: growing) | n/m | +8.73% (above 0%: growing) | 94.90% | 41.18% | Compare |
| BEAM Beam Therapeutics Inc. | $2.6B | — (loss-making) | — (loss-making) | −94.21% (below 0%: shrinking) | n/m | +13.92% (above 0%: growing) | 100.00% | (25,827.14%) | Compare |
| Median of peers | $2.8B | — | — | −38.85% | — | −7.09% | 96.16% | (35.97%) |
Enliven Therapeutics, Inc. (ELVN) key facts
- Enliven Therapeutics, Inc. (ELVN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ELVN traded at $37.32, a market capitalization of $2.9 billion.
- Return on equity was −27.0% and debt-to-equity 0.00.
Enliven Therapeutics, Inc. (ELVN) Latest News
No news at this impact. Lower the threshold for more.